← WEST PHARMACEUTICAL SERVICES INC (WST) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
WEST PHARMACEUTICAL SERVICES INC (WST)
Surgical & Medical Instruments & Apparatus · market cap $26.1B · as of 2026-07-10
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-22 (est.)
Earnings
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
West Pharmaceutical Services (WST) is a mature, profitable manufacturer of injectable pharmaceutical packaging and delivery systems — rubber stoppers, closures, drug delivery devices — not a biotech. Its 'pipeline' entries (Morphine Sulfate, Phenobarbital, Fish Oil, Imetelstat sodium, RVU120) almost certainly reflect customer programs using West's containment/delivery components, not proprietary drug development by WST itself. The company generates ~$3B in annual revenue with consistent profitability and carries net cash of ~$319M.
The catalyst path
- 2026-10-22 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Imetelstat sodium | Phase 2 | Myelodysplastic Syndromes |
| Fish Oil | Phase 2 | Intensive Care Unit |
| Phenobarbital | Phase 3 | Epilepsy |
| RVU120 (SEL120) | Phase 2 | Low Risk Myelodysplastic Syndromes |
Price & technical context
3-month
+1.6%
6-month
+47.9%
12-month
+42.4%
52-wk range
$230.95–$376.63
vs 50-day MA
+5.5%
vs 200-day MA
+23.0%
Realized vol
33.0%
Max drawdown
-45.3%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for WST (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.